Oppenheimer & Co’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Oppenheimer & Co’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-90,613	Closed	-$262K	–	1387
2017 Q3	$262K	Sell	90,613 -4,677	-5%	-$16K	0.01%	1087
2017 Q2	$424K	Buy	95,290 +12,003	+14%	+$49.5K	0.01%	890
2017 Q1	$388K	Buy	+83,287	New	+$483K	0.01%	899
2013 Q4	–	Sell	-75,036	Closed	-$338K	–	1475
2013 Q3	$338K	Buy	75,036 +5,070	+7%	+$22.7K	0.01%	920
2013 Q2	$298K	Buy	+69,966	New	+$352K	0.01%	933

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Oppenheimer & Co's SGYP Position: Q4 2017 in Review

Oppenheimer & Co sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2017, closing a stake of 90,613 shares — an estimated $262K sold.

Oppenheimer & Co first reported a position in SGYP in Q2 2013 and held it in 5 quarters. The position peaked at $424K in Q2 2017. 150 funds tracked by Wall St. Rank hold SGYP as of Q4 2017.

Oppenheimer & Co reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2017 after selling out during the quarter.
Oppenheimer & Co sold 90,613 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2017, an estimated $262K.
Oppenheimer & Co first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 5 quarters.
Oppenheimer & Co's Synergy Pharmaceuticals, Inc Common Stock position peaked at $424K in Q2 2017.
150 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2017.

Based on Oppenheimer & Co's 13F filing for Q4 2017, filed 7 Feb 2018.